US 11,945,880 B2
Heterodimeric antibodies that bind CD3 and tumor antigens
Matthew J. Bernett, Monrovia, CA (US); Gregory Moore, Azusa, CA (US); John Desjarlais, Pasadena, CA (US); Seung Chu, Cypress, CA (US); Rumana Rashid, Temple City, CA (US); Umesh Muchhal, Monrovia, CA (US); and Sung-Hyung Lee, San Gabriel, CA (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Pasadena, CA (US)
Filed on Dec. 3, 2021, as Appl. No. 17/542,342.
Application 17/542,342 is a continuation of application No. 15/141,350, filed on Apr. 28, 2016, granted, now 10,259,887.
Application 15/141,350 is a continuation in part of application No. PCT/US2015/062772, filed on Nov. 25, 2015.
Application PCT/US2015/062772 is a continuation in part of application No. 14/952,714, filed on Nov. 25, 2015, granted, now 10,889,653.
Claims priority of provisional application 62/251,005, filed on Nov. 4, 2015.
Claims priority of provisional application 62/250,971, filed on Nov. 4, 2015.
Claims priority of provisional application 62/159,111, filed on May 8, 2015.
Claims priority of provisional application 62/085,117, filed on Nov. 26, 2014.
Claims priority of provisional application 62/085,027, filed on Nov. 26, 2014.
Claims priority of provisional application 62/085,106, filed on Nov. 26, 2014.
Claims priority of provisional application 62/084,908, filed on Nov. 26, 2014.
Prior Publication US 2022/0162343 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/468 (2013.01) [C07K 16/2809 (2013.01); C07K 16/2866 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/70 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 13 Claims
 
1. A composition comprising a CD3 binding domain, said CD3 binding domain comprising a variable heavy domain and a variable light domain selected from the following:
a) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:20, a vhCDR2 having the amino acid sequence of SEQ ID NO:21, and a vhCDR3 having the amino acid sequence of SEQ ID NO:22; and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:24, a vlCDR2 having the amino acid sequence of SEQ ID NO:25, and a vlCDR3 having the amino acid sequence of SEQ ID NO:26;
b) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:29, a vhCDR2 having the amino acid sequence of SEQ ID NO:30, and a vhCDR3 having the amino acid sequence of SEQ ID NO:31; and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:33, a vlCDR2 having the amino acid sequence of SEQ ID NO:34, and a vlCDR3 having the amino acid sequence of SEQ ID NO:35;
c) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:38, a vhCDR2 having the amino acid sequence of SEQ ID NO:39, and a vhCDR3 having the amino acid sequence of SEQ ID NO:40; and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:42, a vlCDR2 having the amino acid sequence of SEQ ID NO:43, and a vlCDR3 having the amino acid sequence of SEQ ID NO:44; and
d) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:47, a vhCDR2 having the amino acid sequence of SEQ ID NO:48, and a vhCDR3 having the amino acid sequence of SEQ ID NO:49; and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:51, a vlCDR2 having the amino acid sequence of SEQ ID NO:52, and a vlCDR3 having the amino acid sequence of SEQ ID NO:53.